Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab plus Tislelizumab or Rituximab in R/R DLBCL
CTR20220360Phase 2Completed
- Sponsor
- BeiGene
- Start
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ociperlimab in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, sponsored by BeiGene. Started Feb 2022; status: completed.
02
Drugs
ociperlimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on CTR20220360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220360.